The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) reached all time low today, Nov, 3 and still has $8.46 target or 10.00% below today’s $9.40 share price. This indicates more downside for the $211.97M company. This technical setup was reported by Barchart.com. If the $8.46 PT is reached, the company will be worth $21.20 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 7.57% or $0.77 during the last trading session, hitting $9.4. About 392,481 shares traded hands or 1.12% up from the average. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 41.89% since April 1, 2016 and is downtrending. It has underperformed by 43.10% the S&P500.
Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage
Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. Esperion Therapeutics has been the topic of 30 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by Lake Street with “Buy” on Wednesday, June 29. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Outperform” rating by RBC Capital Markets on Tuesday, December 15. The company was downgraded on Wednesday, June 29 by JP Morgan. On Monday, October 26 the stock rating was initiated by Lake Street with “Buy”. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, June 29. The stock has “Overweight” rating given by Barclays Capital on Wednesday, February 24. The rating was maintained by Chardan Capital Markets on Tuesday, September 29 with “Sell”. The rating was upgraded by Needham on Monday, August 10 to “Buy”. On Thursday, February 25 the stock rating was maintained by Stifel Nicolaus with “Buy”. Needham maintained the shares of ESPR in a report on Thursday, June 30 with “Buy” rating.
According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”
Insitutional Activity: The institutional sentiment increased to 1.27 in 2016 Q2. Its up 0.11, from 1.16 in 2016Q1. The ratio is positive, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Susquehanna Int Group Inc Limited Liability Partnership holds 0% or 56,644 shares in its portfolio. Gam Holding Ag accumulated 128,000 shares or 0.02% of the stock. Bvf Inc Il accumulated 499,142 shares or 1.05% of the stock. Citigroup has 0% invested in the company for 12,622 shares. Senzar Asset Lc holds 0% or 219,743 shares in its portfolio. United Ser Automobile Association has 0% invested in the company for 35,280 shares. Pnc Fincl Service Group Inc has 0% invested in the company for 71 shares. Jpmorgan Chase & Com holds 0% or 142,161 shares in its portfolio. Wasatch Incorporated last reported 533,774 shares in the company. Moreover, Ladenburg Thalmann Financial Svcs has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 900 shares. Oxford Asset Management has invested 0.1% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). Rhumbline Advisers has invested 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR). The Pennsylvania-based Federated Inc Pa has invested 0% in Esperion Therapeutics Inc (NASDAQ:ESPR). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 506 shares in its portfolio. California State Teachers Retirement Sys last reported 30,016 shares in the company.
More notable recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on November 22, 2013, also Fool.com with their article: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” published on June 29, 2016, Fool.com published: “Why Esperion Therapeutics, Inc. Stock Cratered Today” on September 29, 2015. More interesting news about Esperion Therapeutics Inc (NASDAQ:ESPR) were released by: Medgadget.com and their article: “Esperion Therapeutics, Inc. Clinical Trial Review, Market Share, Strategy …” published on November 01, 2016 as well as Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR” with publication date: January 14, 2016.
ESPR Company Profile
Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.